001     894308
005     20250813203211.0
024 7 _ |a 10.1093/neuonc/noab036
|2 doi
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a 2128/30320
|2 Handle
024 7 _ |a altmetric:105667813
|2 altmetric
024 7 _ |a pmid:33970242
|2 pmid
024 7 _ |a WOS:000685248000012
|2 WOS
037 _ _ |a FZJ-2021-03168
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Nassiri, Farshad
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Loss of H3K27me3 in meningiomas
260 _ _ |a Oxford
|c 2021
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1754992293_25206
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a BackgroundThere is a critical need for objective and reliable biomarkers of outcome in meningiomas beyond WHO classification. Loss of H3K27me3 has been reported as a prognostically unfavorable alteration in meningiomas. We sought to independently evaluate the reproducibility and prognostic value of H3K27me3 loss by immunohistochemistry (IHC) in a multicenter study.MethodsIHC staining for H3K27me3 and analyses of whole slides from 181 meningiomas across three centers was performed. Staining was analyzed by dichotomization into loss and retained immunoreactivity, and using a 3-tiered scoring system in 151 cases with clear staining. Associations of grouping with outcome were performed using Kaplan-Meier survival estimates.ResultsA total of 21 of 151 tumors (13.9%) demonstrated complete loss of H3K27me3 staining in tumor with retained endothelial staining. Overall, loss of H3K27me3 portended a worse outcome with shorter times to recurrence in our cohort, particularly for WHO grade 2 tumors which were enriched in our study. There were no differences in recurrence-free survival (RFS) for WHO grade 3 patients with retained vs loss of H3K27me3. Scoring by a 3-tiered system did not add further insights into the prognostic value of this H3K27me3 loss. Overall, loss of H3K27me3 was not independently associated with RFS after controlling for WHO grade, extent of resection, sex, age, and recurrence status of tumor on multivariable Cox regression analysis.ConclusionsLoss of H3K27me3 identifies a subset of WHO grade 2 and possibly WHO grade 1 meningiomas with increased recurrence risk. Pooled analyses of a larger cohort of samples with standardized reporting of clinical definitions and staining patterns are warranted.
536 _ _ |a 5252 - Brain Dysfunction and Plasticity (POF4-525)
|0 G:(DE-HGF)POF4-5252
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Wang, Justin Z
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Singh, Olivia
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Karimi, Shirin
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Dalcourt, Tatyana
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Ijad, Nazanin
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Pirouzmand, Neda
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Ng, Ho-Keung
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Saladino, Andrea
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Pollo, Bianca
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Dimeco, Francesco
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Yip, Stephen
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Gao, Andrew
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Aldape, Kenneth D
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Zadeh, Gelareh
|0 P:(DE-HGF)0
|b 14
|e Corresponding author
700 1 _ |a Aldape, Kenneth
|0 P:(DE-HGF)0
|b 15
700 1 _ |a Au, Karolyn
|0 P:(DE-HGF)0
|b 16
700 1 _ |a Barnholtz-Sloan, Jill
|0 P:(DE-HGF)0
|b 17
700 1 _ |a Behling, Felix
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Bi, Wenya
|0 P:(DE-HGF)0
|b 19
700 1 _ |a Brastianos, Priscilla
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Butowski, Nicholas
|0 P:(DE-HGF)0
|b 21
700 1 _ |a Brodie, Chaya
|0 P:(DE-HGF)0
|b 22
700 1 _ |a Cohen-Gadol, Aaron
|0 P:(DE-HGF)0
|b 23
700 1 _ |a Couce, Marta
|0 P:(DE-HGF)0
|b 24
700 1 _ |a Dimeco, Francesco
|0 P:(DE-HGF)0
|b 25
700 1 _ |a Drummond, Kate
|0 P:(DE-HGF)0
|b 26
700 1 _ |a Dunn, Ian
|0 P:(DE-HGF)0
|b 27
700 1 _ |a Cohen-Gadol, Aaron
|0 P:(DE-HGF)0
|b 28
700 1 _ |a Galanis, Eva
|0 P:(DE-HGF)0
|b 29
700 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 30
700 1 _ |a Giannini, Caterina
|0 P:(DE-HGF)0
|b 31
700 1 _ |a Goldbrunner, Roland
|0 P:(DE-HGF)0
|b 32
700 1 _ |a Hanemann, Oliver
|0 P:(DE-HGF)0
|b 33
700 1 _ |a Herold-Mende, Christel
|0 P:(DE-HGF)0
|b 34
700 1 _ |a Horbinski, Craig
|0 P:(DE-HGF)0
|b 35
700 1 _ |a Huang, Raymond
|0 P:(DE-HGF)0
|b 36
700 1 _ |a Javadpour, Mohsen
|0 P:(DE-HGF)0
|b 37
700 1 _ |a Jenkinson, Michael
|0 P:(DE-HGF)0
|b 38
700 1 _ |a Jungk, Christine
|0 P:(DE-HGF)0
|b 39
700 1 _ |a Kaufmann, Timothy
|0 P:(DE-HGF)0
|b 40
700 1 _ |a Krischek, Boris
|0 P:(DE-HGF)0
|b 41
700 1 _ |a Kurz, Sylvia
|0 P:(DE-HGF)0
|b 42
700 1 _ |a Lachance, Daniel
|0 P:(DE-HGF)0
|b 43
700 1 _ |a Lafougere, Christian
|0 P:(DE-HGF)0
|b 44
700 1 _ |a Lamszus, Katrin
|0 P:(DE-HGF)0
|b 45
700 1 _ |a Lee, Ian
|0 P:(DE-HGF)0
|b 46
700 1 _ |a Malta, Tathiana
|0 P:(DE-HGF)0
|b 47
700 1 _ |a Makarenko, Serge
|0 P:(DE-HGF)0
|b 48
700 1 _ |a Mawrin, Christian
|0 P:(DE-HGF)0
|b 49
700 1 _ |a McDermott, Michael
|0 P:(DE-HGF)0
|b 50
700 1 _ |a Millward, Christopher
|0 P:(DE-HGF)0
|b 51
700 1 _ |a Moliterno-Gunel, Jennifer
|0 P:(DE-HGF)0
|b 52
700 1 _ |a Morokoff, Andrew
|0 P:(DE-HGF)0
|b 53
700 1 _ |a Nassiri, Farshad
|0 P:(DE-HGF)0
|b 54
700 1 _ |a Ng, H. K.
|0 P:(DE-HGF)0
|b 55
700 1 _ |a Noushmehr, Houtan
|0 P:(DE-HGF)0
|b 56
700 1 _ |a Perry, Arie
|0 P:(DE-HGF)0
|b 57
700 1 _ |a Poisson, Laila
|0 P:(DE-HGF)0
|b 58
700 1 _ |a Pollo, Bianco
|0 P:(DE-HGF)0
|b 59
700 1 _ |a Ragunathan, Aditya
|0 P:(DE-HGF)0
|b 60
700 1 _ |a Raleigh, David
|0 P:(DE-HGF)0
|b 61
700 1 _ |a Renovanz, Mirjam
|0 P:(DE-HGF)0
|b 62
700 1 _ |a Ricklefs, Franz
|0 P:(DE-HGF)0
|b 63
700 1 _ |a Sahm, Felix
|0 P:(DE-HGF)0
|b 64
700 1 _ |a Saladino, Andrea
|0 P:(DE-HGF)0
|b 65
700 1 _ |a Santacroce, Antonio
|0 P:(DE-HGF)0
|b 66
700 1 _ |a Santarius, Thomas
|0 P:(DE-HGF)0
|b 67
700 1 _ |a Schichor, Christian
|0 P:(DE-HGF)0
|b 68
700 1 _ |a Schimdt, Nils
|0 P:(DE-HGF)0
|b 69
700 1 _ |a Schittenhelm, Jens
|0 P:(DE-HGF)0
|b 70
700 1 _ |a Selman, Warren
|0 P:(DE-HGF)0
|b 71
700 1 _ |a Shih, Helen
|0 P:(DE-HGF)0
|b 72
700 1 _ |a Snyder, Jim
|0 P:(DE-HGF)0
|b 73
700 1 _ |a Snuderl, Matja
|0 P:(DE-HGF)0
|b 74
700 1 _ |a Sloan, Andrew
|0 P:(DE-HGF)0
|b 75
700 1 _ |a Suppiah, Suganth
|0 P:(DE-HGF)0
|b 76
700 1 _ |a Sulman, Erik
|0 P:(DE-HGF)0
|b 77
700 1 _ |a Tabatabai, Ghazaleh
|0 P:(DE-HGF)0
|b 78
700 1 _ |a Tatagiba, Marcos
|0 P:(DE-HGF)0
|b 79
700 1 _ |a Timmer, Marcos
|0 P:(DE-HGF)0
|b 80
700 1 _ |a Tonn, Joerg-Christian
|0 P:(DE-HGF)0
|b 81
700 1 _ |a Von Deimling, Andreas
|0 P:(DE-HGF)0
|b 82
700 1 _ |a Vogelbaum, Michael
|0 P:(DE-HGF)0
|b 83
700 1 _ |a Walbert, Tobias
|0 P:(DE-HGF)0
|b 84
700 1 _ |a Wang, Justin
|0 P:(DE-HGF)0
|b 85
700 1 _ |a Wen, Patrick
|0 P:(DE-HGF)0
|b 86
700 1 _ |a Westphal, Manfred
|0 P:(DE-HGF)0
|b 87
700 1 _ |a Yip, Stephen
|0 P:(DE-HGF)0
|b 88
700 1 _ |a Zadeh, Gelareh
|0 P:(DE-HGF)0
|b 89
|e Corresponding author
773 _ _ |a 10.1093/neuonc/noab036
|g Vol. 23, no. 8, p. 1282 - 1291
|0 PERI:(DE-600)2094060-9
|n 8
|p 1282 - 1291
|t Neuro-Oncology
|v 23
|y 2021
|x 1523-5866
856 4 _ |u https://juser.fz-juelich.de/record/894308/files/Nassiri_2021_NeuroOncology_post-print.pdf
|y Published on 2021-05-10. Available in OpenAccess from 2022-05-10.
856 4 _ |u https://juser.fz-juelich.de/record/894308/files/noab036.pdf
|y Restricted
909 C O |o oai:juser.fz-juelich.de:894308
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 30
|6 P:(DE-Juel1)143792
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5252
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-02-03
915 _ _ |a Embargoed OpenAccess
|0 StatID:(DE-HGF)0530
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2019
|d 2021-02-03
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b NEURO-ONCOLOGY : 2019
|d 2021-02-03
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-02-03
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-02-03
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-02-03
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a UNRESTRICTED
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21